Patients assigned bimagrumab in the clinical trial received IV infusions of the drug at weeks 4, 16, 28 and 40
Some users report decreased energy and motivation for exercise, especially in the first 4-8 weeks
If you want clarity on a specific lab value or testing scenario, bring the result, your dose timeline, and a brief symptom log to your clinician
The key is working with a provider who pays attention to your whole health picture, not just your weight
This is in large part due to the fact that it is one of the best products in the market today
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unlicensed by the MHRA or EMA and still being evaluated in Phase 2 and Phase 3 clinical trials